Use of levodopa-carbidopa intestinal gel ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
Use of levodopa-carbidopa intestinal gel to treat patients with multiple system atrophy.
Auteur(s) :
Blaise, A. S. [Auteur]
Service de neurologie et pathologie du mouvement
Cuvelier, Elodie [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Carrière, N. [Auteur]
Service de neurologie et pathologie du mouvement
DEVOS, DAVID [Auteur]
Lille Neurosciences & Cognition (LilNCog) - U 1172
Moreau, F. [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Defebvre, L. [Auteur]
Service de neurologie et pathologie du mouvement
Mutez, Eugenie [Auteur]
Lille Neurosciences & Cognition (LilNCog) - U 1172
Service de neurologie et pathologie du mouvement
Cuvelier, Elodie [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Carrière, N. [Auteur]
Service de neurologie et pathologie du mouvement
DEVOS, DAVID [Auteur]
Lille Neurosciences & Cognition (LilNCog) - U 1172
Moreau, F. [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Defebvre, L. [Auteur]
Service de neurologie et pathologie du mouvement
Mutez, Eugenie [Auteur]
Lille Neurosciences & Cognition (LilNCog) - U 1172
Titre de la revue :
Parkinsonism and Related Disorders
Nom court de la revue :
Parkinsonism Relat Disord
Numéro :
100
Pagination :
41-44
Éditeur :
Elsevier
Date de publication :
2022-06-23
ISSN :
1873-5126
Mot(s)-clé(s) :
Multiple system atrophy
Motor fluctuations
Continuous dopaminergic stimulation
Levodopa-carbidopa intestinal gel
Levodopa-responsiveness
Motor fluctuations
Continuous dopaminergic stimulation
Levodopa-carbidopa intestinal gel
Levodopa-responsiveness
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Background
Levodopa-carbidopa intestinal gel (LCIG) is an effective treatment for late-stage Parkinson's disease (PD) but had not been evaluated in levodopa-responsive patients with the parkinsonian variant of multiple ...
Lire la suite >Background Levodopa-carbidopa intestinal gel (LCIG) is an effective treatment for late-stage Parkinson's disease (PD) but had not been evaluated in levodopa-responsive patients with the parkinsonian variant of multiple system atrophy (MSA-P) and motor fluctuations. We aimed to assess the safety of LCIG in MSA-P patients. Methods In a retrospective, single-center study, we analyzed clinical and treatment-related data for all patients with MSA-P or PD treated with LCIG between December 2004 and November 2017. Adverse events (AEs) were classified into three classes: AEs related to gastrointestinal effects or to the PEG-J procedure, AEs related to the device, and AEs related to the pharmacological effect of LCIG. Results 7 MSA-P and 63 PD patients had been treated with LCIG for a median [interquartile range] period of 31 [16;43] and 19 [8;45] months, respectively. There were no significant intergroup differences in safety. Enteral nutrition was introduced at the same time as LCIG treatment in 4 (57%) MSA-P patients. In the MSA-P and PD groups, LCIG was associated with a better Global Clinical Impression score and discontinuation of oral anti-parkinsonian drugs (in 43% and 27% of cases, respectively). Conclusions LCIG treatment is feasible in MSA-P patients with severe motor complications. The safety profile is similar to that seen in PD.Lire moins >
Lire la suite >Background Levodopa-carbidopa intestinal gel (LCIG) is an effective treatment for late-stage Parkinson's disease (PD) but had not been evaluated in levodopa-responsive patients with the parkinsonian variant of multiple system atrophy (MSA-P) and motor fluctuations. We aimed to assess the safety of LCIG in MSA-P patients. Methods In a retrospective, single-center study, we analyzed clinical and treatment-related data for all patients with MSA-P or PD treated with LCIG between December 2004 and November 2017. Adverse events (AEs) were classified into three classes: AEs related to gastrointestinal effects or to the PEG-J procedure, AEs related to the device, and AEs related to the pharmacological effect of LCIG. Results 7 MSA-P and 63 PD patients had been treated with LCIG for a median [interquartile range] period of 31 [16;43] and 19 [8;45] months, respectively. There were no significant intergroup differences in safety. Enteral nutrition was introduced at the same time as LCIG treatment in 4 (57%) MSA-P patients. In the MSA-P and PD groups, LCIG was associated with a better Global Clinical Impression score and discontinuation of oral anti-parkinsonian drugs (in 43% and 27% of cases, respectively). Conclusions LCIG treatment is feasible in MSA-P patients with severe motor complications. The safety profile is similar to that seen in PD.Lire moins >
Langue :
Anglais
Audience :
Internationale
Établissement(s) :
Université de Lille
CHU Lille
CHU Lille
Collections :
Date de dépôt :
2023-05-25T02:35:27Z
2023-07-05T07:10:33Z
2023-07-05T07:10:33Z